Company Overview and News

 
No strong sales uplift from GST zero-rating seen for DKSH

2018-08-17 theedgemarkets
DKSH Holdings (Malaysia) Bhd (Aug 16, RM3.81) Downgrade to neutral with a lower target price (TP) of RM4.25: We met with DKSH Holdings (Malaysia) Bhd’s management recently to get updates on its performance and outlook. Based on preliminary estimates, sales are not expected to pick up strongly during the three-month tax holiday when the country’s system migrates from the goods and services tax (GST) to the sales and service tax (SST).
DKSHY DKSHF 5908

 
KLCI seen rising amid global relief rally, support at 1,773

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): The FBM KLCI is seen rising amid some overnight relief rally at most global markets, immediate support at 1,773.
7158 DKSHY 6912 KLKBY 2445 4995 5225 6238 4405 1899 Q0F IHHHF 5908 DKSHF

7
AirAsia, Batu Kawan, KLK, DKSH, Hock Seng Lee, IHH, Nestlé, Pasdec, Scomi, Tan Chong, Versatile Creative and YTL REIT

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): Based on corporate announcements and news flow today, stocks in focus tomorrow may include: AirAsia Group Bhd, Batu Kawan Bhd, Kuala Lumpur Kepong Bhd, DKSH Holdings (M) Bhd, Hock Seng Lee Bhd, IHH Healthcare Bhd, Nestlé (Malaysia) Bhd, Pasdec Holdings Bhd, Scomi Group Bhd, Tan Chong Motor Holdings Bhd, Versatile Creative Bhd and YTL YTL Hospitality REIT.
SLLXF 7158 532843 DKSHY 6912 KLKBY 2445 4995 EXPE 5225 FORTIS 6238 5109 4405 1899 Q0F IHHHF 5908 DKSHF

 
DKSH to sell Famous Amos cookies in Brunei

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): DKSH Holdings (Malaysia) Bhd plans to expand its chocolate chip cookies and chocolate-related businesses under the Famous Amos brand to Brunei after setting up a new sub-subsidiary there.
DKSHY BSMAF DKSHF 5908 1818

 
DKSH likely to post rise in 3Q profit on higher consumer spending

2018-08-10 theedgemarkets
DKSH Holdings (Malaysia) Bhd (Aug 9, RM3.82) Maintain outperform with an unchanged target price of RM5: Revenue in the second quarter ended June 30, 2018 (2QFY18) grew 3.5% year-on-year (y-o-y) to RM1.44 billion. The growth in revenue was largely due to organic growth in DKSH Holdings (Malaysia) Bhd’s existing businesses. The logistics segment posted stronger revenue growth of 6% while revenue for the marketing and distribution segment was flattish, growing at about 0.
DKSHY DKSHF 5908

 
KLCI gets off on a flat note, tracks subdued region

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): The FBM KLCI started on a flast note this morning, tracking its subdued regional peers.
PBLOF 5183 PECGF 1295 DKSHY 2852 5347 3301 3867 5209 TNABY TNABF 5908 DKSHF

 
DKSH net profit down 14% due to higher operating costs

2018-08-09 thestar.com.my
For the cumulative period, the group’s net profit fell 5.8% to RM24.86mil for the six months to June 2018 from RM26.4mil previously.
DKSHY DKSHF 5908

 
KLCI seen trending sideways, immediate hurdle at 1,809

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 9): The FBM KLCI is seen trending sideways today with immediate hurdle at 1,809 in line with the global markets where trade jitters kept sentiment in check.
DKSHY 5209 5162 0151 5123 DKSHF 5908

 
Gas Malaysia, Axis REIT, Perak Corp, Kelington Group, Zecon, IJM Corp, ECS ICT, DKSH, MQReit and AirAsia

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 8): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Gas Malaysia Bhd, Axis REIT, Perak Corp Bhd, Kelington Group Bhd, Zecon Bhd, IJM Corp Bhd, ECS ICT Bhd, DKSH Holdings (Malaysia) Bhd, MRCB-Quill REIT and AirAsia Group Bhd.
DKSHY FLY 5209 5162 0151 5123 DKSHF 5908

 
Higher operating expenses eat into DKSH's 2Q profit

2018-08-08 theedgemarkets
KUALA LUMPUR: DKSH Holdings (Malaysia) Bhd registered a 14% year-on-year decline in its net profit for the second quarter ended June 30, 2018 (2QFY18), as rising operating expenditure offset growth in the group's quarterly revenue.
DKSHY DKSHF 5908

 
KLCI struggles to climb higher as sentiment stays tepid

2018-07-30 theedgemarkets
KUALA LUMPUR (July 30): The FBM KLCI struggled to climb higher at mid-morning today as sentiment at the local bourse stayed tepid in line with regional markets.
7113 7036 BATS TPGVF 4162 DKSHY 5029 3026 5225 3867 7722 2739 IHHHF PNAGF 5908 5681 6033 7123 TGLVY PNADF 2542 1899 Q0F 3719 DKSHF

 
DKSH Holdings Ltd. ADR 2018 Q2 - Results - Earnings Call Slides

2018-07-12 seekingalpha
The following slide deck was published by DKSH Holdings Ltd. ADR in conjunction with their 2018 Q2 earnings call.
DKSHY DKSHF 5908

17
KLCI falls 0.47% in subdued start to 2H2018

2018-07-02 theedgemarkets
KUALA LUMPUR (July 2): The FBM KLCI fell 0.47% at midday break today, as latest data showed business conditions across Malaysia’s manufacturing sector deteriorating, albeit at a slower pace in June.
HLFBF PBLOF 7113 7036 TPGVF 1295 7077 9334 DKSHY 5347 3301 8613 TNABY 5908 HRGHY SPMXF 1082 5681 5168 1481 TGLVY 5139 4588 SPMXY 0900 5819 TNABF DKSHF

18
KLCI remains in the red in slow start to 2H2018

2018-07-02 theedgemarkets
KUALA LUMPUR (July 2): The FBM KLCI remained subdued at mid-morning today after data showed business conditions across Malaysia’s manufacturing sector deteriorating albeit at a slower pace in June.
7052 PBLOF BATS 4162 1295 3794 2089 7077 5199 DKSHY KLKBY 3867 7206 HIPEF 5908 SPMXF UPBMF 8133 1481 5139 2445 4588 SPMXY 0026 0900 5819 DKSHF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...